Breathe Well Live Well
Conditions: Asthma; Moderate Asthma
Interventions: Drug: REGN3500; Drug: Placebo
Sponsors: Regeneron Pharmaceuticals; Sanofi
Not yet recruiting – verified December 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
 |
Related Articles |
Multiple health benefits of urban tree canopy: The mounting evidence for a green prescription.
Health Place. 2016 Sep 14;42:54-62
Authors: Ulmer JM, Wolf KL, Backman DR, Tretheway RL, Blain CJ, O’Neil-Dunne JP, Frank LD
Abstract
The purpose of this study was to enhance the understanding of the health-promoting potential of trees in an urbanized region of the United States. This was done using high-resolution LiDAR and imagery data to quantify tree cover within 250m of the residence of 7910 adult participants in the California Health Interview Survey, then testing for main and mediating associations between tree cover and multiple health measures. The results indicated that more neighborhood tree cover, independent from green space access, was related to better overall health, primarily mediated by lower overweight/obesity and better social cohesion, and to a lesser extent by less type 2 diabetes, high blood pressure, and asthma. These findings suggest an important role for trees and nature in improving holistic population health in urban areas.
PMID: 27639106 [PubMed – as supplied by publisher]
View full post on pubmed: asthma
|
Inhaling cane smoke is one of multiple asthma triggers
Maui News Some people are easily amazed. Like the verbose contributor (Letters, Oct. 18) who appears to extol the virtues of inhaling cane smoke. Perhaps we should all gather around the fires and breathe deeply to become symptomatic immediately. Most asthmatics … |
View full post on asthma – Google News
| Related Articles |
Desensitization to ceftaroline in a patient with multiple medication hypersensitivity reactions.
Am J Health Syst Pharm. 2015 Feb 1;72(3):198-202
Authors: Jones JM, Richter LM, Alonto A, Leedahl DD
Abstract
PURPOSE: The case of a patient with multiple medication hypersensitivity reactions and a methicillin-resistant Staphylococcus aureus (MRSA) infection who underwent desensitization to ceftaroline is reported.
SUMMARY: A 32-year-old Caucasian woman with asthma, gastroesophageal reflux disease, heart murmur, and major depression was admitted for MRSA cellulitis with a subcutaneous abscess along the left sternomanubrial joint and clavicular osteomyelitis secondary to port placement after gastric bypass surgery. The patient had an extensive history of hypersensitivity reactions. Pertinent documented allergies were as follows: penicillin (anaphylaxis), daptomycin (anaphylaxis), vancomycin (hives), linezolid (hives), ertapenem (rash), ciprofloxacin (rash), and tigecycline (rash). The patient also reported previous reactions to aztreonam (unknown) and gentamicin (hives). The pharmacy was consulted to develop a desensitization protocol for ceftaroline. The desensitization protocol used three serial dilutions of ceftaroline to make 14 sequential infusions with escalating doses. Intramuscular epinephrine, i.v. diphenhydramine, and i.v. methylprednisolone were ordered as needed for the development of immediate hypersensitivity reactions during or after administration of ceftaroline. The cumulative dose (574.94 mg) was administered intravenously over 225 minutes with no breakthrough symptoms reported during or after the desensitization protocol. Ceftaroline fosamil 600 mg i.v. every 12 hours was continued for six weeks.
CONCLUSION: Desensitization to ceftaroline was conducted for a patient with extensive history of hypersensitivity reactions to other drugs, including penicillin-induced anaphylaxis. Desensitization and subsequent treatment with full doses of ceftaroline were accomplished without apparent adverse effects.
PMID: 25596602 [PubMed – in process]
View full post on pubmed: asthma
Condition: Asthma
Interventions: Drug: PBF-680; Drug: Placebo
Sponsors: Fundació Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau; Palo Biofarma, S.L
Recruiting – verified August 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Condition: Asthma
Interventions: Drug: Placebo to BI 1060469; Drug: BI 1060469 Healthy; Drug: Placebo to BI 1060469 asthmatics; Drug: BI 1060469 asthmatics
Sponsor: Boehringer Ingelheim
Not yet recruiting – verified April 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
RedOrbit |
Asthma Drug Helps Desensitize People To Multiple Food Allergens At Once
RedOrbit New research from Stanford University and Johns Hopkins Medical School has shown that an asthma drug can be used to help desensitize people to several food allergens all at once, according to a new report in the journal Allergy, Asthma & Clinical … Asthma drug aids simultaneous desensitization to several food allergies, study … Asthma Drug Aids Simultaneous Desensitization to Food Allergies Asthma drug helps relieve food allergies, study finds |
View full post on asthma – Google News
|
Medications offer multiple ways to treat asthma
Tulsa World There are both long-acting types and short-acting types. The long-acting types are controllers: They are used to reduce the number of asthma attacks and are usually prescribed for daily use. The short-acting types are relievers, used to stop an asthma … |
View full post on asthma – Google News
 |
Multiple In Vitro and In Vivo Regulatory Effects of Budesonide in CD4+ T Lymphocyte Subpopulations of Allergic Asthmatics.
PLoS One. 2012;7(12):e48816
Authors: Pace E, Di Sano C, La Grutta S, Ferraro M, Albeggiani G, Liotta G, Di Vincenzo S, Uasuf CG, Bousquet J, Gjomarkaj M
Abstract
BACKGROUND: Increased activation and increased survival of T lymphocytes characterise bronchial asthma.
OBJECTIVES: In this study the effect of budesonide on T cell survival, on inducible co-stimulator T cells (ICOS), on Foxp3 and on IL-10 molecules in T lymphocyte sub-populations was assessed.
METHODS: Cell survival (by annexin V binding) and ICOS in total lymphocytes, in CD4+/CD25+ and in CD4+/CD25- and Foxp3 and IL-10 in CD4+/CD25+ and in CD4+/CD25-cells was evaluated, by cytofluorimetric analysis, in mild intermittent asthmatics (n?=?19) and in controls (n?=?15). Allergen induced T lymphocyte proliferation and the in vivo effects of budesonide in mild persistent asthmatics (n?=?6) were also explored.
RESULTS: Foxp3 was reduced in CD4+/CD25- and in CD4+/CD25+ cells and ICOS was reduced in CD4+/CD25+ cells but it was increased in CD4+CD25-in asthmatics when compared to controls. In asthmatics, in vitro, budesonide was able to: 1) increase annexin V binding and to reduce ICOS in total lymphocytes; 2) increase annexin V binding and Foxp3 and to reduce ICOS in CD4+/CD25- cells; 3) reduce annexin V binding and to increase IL-10 and ICOS in CD4+/CD25+ cells; 4) reduce cell allergen induced proliferation. In vivo, budesonide increased ICOS in CD4+/CD25+ while it increased Foxp3 and IL-10 in CD4+/CD25+ and in CD4+/CD25- cells.
CONCLUSIONS: Budesonide modulates T cell survival, ICOS, Foxp3 and IL-10 molecules differently in T lymphocyte sub-populations. The findings provided shed light on new mechanisms by which corticosteroids, drugs widely used for the clinical management of bronchial asthma, control T lymphocyte activation.
PMID: 23251336 [PubMed – in process]
View full post on pubmed: asthma
|
Nanoparticles Stop Multiple Sclerosis In Mice and could treat food allergies …
Next Big Future Nanoparticles Stop Multiple Sclerosis In Mice and could treat food allergies, asthma and other autoimmune diseases · Email ThisBlogThis!Share to TwitterShare to Facebook · Tweet · NBC News – Researchers trying to find a way to treat multiple sclerosis … |
View full post on asthma – Google News